vTv Therapeutics Files 8-K on Shareholder Matters

TL;DR

vTv Therapeutics filed an 8-K on shareholder votes, based in NC.

AI Summary

vTv Therapeutics Inc. filed an 8-K on June 14, 2024, reporting on matters submitted to a vote of security holders as of June 11, 2024. The filing details the company's corporate structure, including its state of incorporation (Delaware) and fiscal year end (December 31). The company's principal executive offices are located in High Point, North Carolina.

Why It Matters

This filing provides an update on corporate governance and shareholder voting matters for vTv Therapeutics Inc., which is important for investors to understand the company's decision-making processes.

Risk Assessment

Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new financial or operational risks.

Key Numbers

• 001-37524 — SEC File Number (Identifies the company's filing history with the SEC.)
• 47-3916571 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• vTv Therapeutics Inc. (company) — Registrant
• June 11, 2024 (date) — Earliest event reported
• June 14, 2024 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• High Point, NC (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.01 — stered Class A common stock, par value $0.01 per share VTVT NASDAQ Capital Market

Filing Documents

• vtvt-20240611.htm (8-K) — 41KB
• 0001641489-24-000045.txt ( ) — 162KB
• vtvt-20240611.xsd (EX-101.SCH) — 2KB
• vtvt-20240611_lab.xml (EX-101.LAB) — 21KB
• vtvt-20240611_pre.xml (EX-101.PRE) — 12KB
• vtvt-20240611_htm.xml (XML) — 3KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On June 11, 2024, vTv Therapeutics Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). The matters voted on at the Annual Meeting and the votes cast with respect to each such matter are set forth below: (1) Based on the following results of the voting, the Company's stockholders elected the nominees listed below to the Company's Board of Directors, each to serve for a term to expire at the Company's 2025 annual meeting of stockholders or until their successors are duly elected and qualified: Director Nominee For Withheld Broker Non Votes Srinivas Akkaraju 1,912,870 7,825 294,269 Raymond Cheong 1,913,019 7,676 294,269 Fahed Al Marzooqi 1,887,098 33,597 294,269 Richard S. Nelson 1,913,112 7,583 294,269 Anne Phillips 1,913,111 7,584 294,269 Paul Sekhri 1,913,689 7,006 294,269 Daniel K. Spiegelman 1,913,127 7,568 294,269 (2) The Company's stockholders approved the adoption of the 2024 Equity Incentive Plan based upon the following results of the voting: For Against Abstain Broker Non Votes 1,814,842 103,928 1,925 294,269 (3) The appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024, was ratified based on the following results of the voting: For Against Abstain Broker Non Votes 2,106,193 9,580 99,191 0

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. VTV THERAPEUTICS INC. By: /s/ Paul J. Sekhri Name: Paul J. Sekhri Title: Chairman, President, and Chief Executive Officer Dated: June 14, 2024

View Full Filing

View this 8-K filing on SEC EDGAR